Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.

摘要: To determine the long-term efficacy, safety, and toxicity of omeprazole, we studied 40 patients with Zollinger-Ellison syndrome given omeprazole for 6-51 mo (median 29). The mean daily dose required to control gastric acid secretion was 82 +/- 31 mg. Thirty-one once per day. In 9 output not controlled by 120 mg day, but 60 every 12 h. correlated previous histamine H2-receptor antagonist (r = 0.89, p less than 0.001), basal 0.43, 0.01), maximal 0.39, 0.02) serum concentration gastrin -0.32). Increases in were patients. Twenty-nine had mild peptic symptoms outputs 10 mEq/h while taking antagonists. Symptoms resolved completely 23 partially 3 when omeprazole. Omeprazole prevented mucosal disease all including 17 whom antagonists produced only partial resolution despite being those during therapy. therapy associated any significant side effects, nor evidence hematologic or biochemical toxicity. Serum concentrations did change significantly 6 treated 1 yr there no output. patients, morphology histopathology demonstrated carcinoid formation. These results demonstrate that treatment up 4 yr, is safe, hematologic, biochemical, Furthermore, remained effective, 23% requiring an increase dose, continued who been entirely symptom-free high doses now drug choice syndrome.